Despite the numerous observed differences in mutation rate and number of predicted neoantigens, both virus-positive MCC and virus-negative MCC tumors have shown high response rates to PD-L1 and PD1 checkpoint blockade therapy [14, 15]. The gene discussed is CD274; the disease is Merkel cell skin cancer.